biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its ...
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
IRVING, Texas--(BUSINESS WIRE)-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...
IRVING, Texas, April 23, 2025--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized ...
Peterson stated, "we reiterate our fiscal 2025 revenue guidance of above $190 million and our fiscal 2025 adjusted EBITDA guidance of above $50 million." Management continues to expect mid-teens ...
IRVING, Texas, July 23, 2025--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized ...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator advancing the healthspan of patients’ lives by providing hormone replacement therapy and healthy aging solutions, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results